Mayinglong Pharmaceutical Group Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Mayinglong Pharmaceutical Group Co., Ltd. carries a market capitalization of 9.98B, placing it among publicly traded companies globally. Its enterprise value stands at 9.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.98B |
| Enterprise Value | 9.61B |
Share Statistics
Mayinglong Pharmaceutical Group Co., Ltd. currently has 431.05M shares outstanding.
| Shares Outstanding | 431.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Mayinglong Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 21.90. The price-to-sales ratio is 3.27, and the price-to-book ratio stands at 3.21.
| PE Ratio | 21.90 |
| PS Ratio | 3.27 |
| PB Ratio | 3.21 |
| P/TBV Ratio | 3.04 |
| P/FCF Ratio | 72.09 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Mayinglong Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 15.02 and an EV/FCF ratio of 54.97. The EV/Sales ratio of 2.56 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.02 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.56 |
| EV / EBITDA | 15.02 |
| EV / EBIT | 15.02 |
| EV / FCF | 54.97 |
Financial Position
Mayinglong Pharmaceutical Group Co., Ltd. maintains a current ratio of 3.35, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.74, indicating elevated leverage, while an interest coverage ratio of 108.75 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.35 |
| Quick Ratio | 2.46 |
| Debt / Equity | 4.74 |
| Debt / EBITDA | 0.32 |
| Interest Coverage | 108.75 |
Financial Efficiency
Mayinglong Pharmaceutical Group Co., Ltd. posts a return on equity of 15.23 and a return on invested capital of 12.12.
| Return on Equity (ROE) | 15.23 |
| Return on Assets (ROA) | 10.33 |
| Return on Invested Capital (ROIC) | 12.12 |
| Return on Capital Employed (ROCE) | 13.44 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.91 |
Taxes
Over the trailing twelve months, Mayinglong Pharmaceutical Group Co., Ltd. has paid 107.93M in income taxes, reflecting an effective tax rate of 15.64.
| Income Tax | 107.93M |
| Effective Tax Rate | 15.64 |
Stock Price Statistics
Mayinglong Pharmaceutical Group Co., Ltd.'s stock has declined approximately -15.10818% over the past 52 weeks. The 50-day moving average sits at 24.16, while the 200-day moving average is 26.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | -15.10818% |
| 50-Day Moving Average | 24.16 |
| 200-Day Moving Average | 26.56 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mayinglong Pharmaceutical Group Co., Ltd. generated 3.75B in revenue and converted that into 559.40M in net income, yielding earnings per share of 1.34. EBITDA reached 640.04M, while operating income came in at 640.04M.
| Revenue | 3.75B |
| Gross Profit | 1.77B |
| Operating Income | 640.04M |
| Pretax Income | 689.96M |
| Net Income | 559.40M |
| EBITDA | 640.04M |
| EBIT | 640.04M |
| Earnings Per Share (EPS) | 1.34 |
Balance Sheet
Mayinglong Pharmaceutical Group Co., Ltd. holds 2.97B in cash and equivalents against 202.42M in total debt, resulting in a net debt position of -1.70B. Total book value stands at 3.82B, with working capital of 2.84B providing operational flexibility.
| Cash & Cash Equivalents | 2.97B |
| Total Debt | 202.42M |
| Net Debt | -1.70B |
| Equity (Book Value) | 3.82B |
| Book Value Per Share | 8.82 |
| Working Capital | 2.84B |
Cash Flow
After subtracting -169.91M in capital expenditures, free cash flow totaled -169.91M - equivalent to -0.39 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -169.91M |
| Free Cash Flow | -169.91M |
| FCF Per Share | -0.39 |
Margins
Mayinglong Pharmaceutical Group Co., Ltd. operates with a gross margin of 47.20, reflecting its pricing power and cost economics. The operating margin of 17.07 and net profit margin of 14.92 provide insight into operational efficiency.
| Gross Margin | 47.20 |
| Operating Margin | 17.07 |
| Pretax Margin | 18.40 |
| Profit Margin | 14.92 |
| EBITDA Margin | 17.07 |
Dividends & Yields
The company's payout ratio of 28.95 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.40 |
| Dividend Yield | N/A |
| Payout Ratio | 28.95 |
| Shareholder Yield | 2.43 |
| FCF Yield | 1.39 |
Stock Splits
Mayinglong Pharmaceutical Group Co., Ltd.'s most recent stock split took place on July 21, 2015 with a 10:13 split ratio.
| Last Split Date | 7/21/2015 |
| Split Ratio | 10:13 |
Scores
Mayinglong Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 7.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.99 |